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412 The Journal of Thoracic and Card 
he article by Lederer and colleagues1 in this issue of the Journal reports on
a small series of patients with end-stage emphysema undergoing lung-
volume reduction surgery (LVRS) with good clinical results and amazingly
ow morbidity and mortality. The purpose of the article is to correlate improvements
n clinical status with the body mass index, airflow obstruction, dyspnea, and
xercise capacity (BODE) index, a multidimensional predictor of survival in pa-
ients with chronic obstructive pulmonary disease. The authors suggest that the
ODE index may eventually prove useful as a surrogate to predict survival not only
or patients with chronic obstructive pulmonary disease, but for those with end-stage
mphysema undergoing LVRS. Their conclusions regarding the BODE index,
owever, must be regarded with caution because of a number of inherent limitations
n their study. First, as the authors themselves point out, the study includes a small
umber of patients operated on at a single center with a relatively short follow-up. 1
erhaps more importantly, however, the BODE index itself appears to have inherent
imitations that could prevent it from proving useful in the subset of patients
ndergoing LVRS. The BODE index was designed to assess chronic obstructive
ulmonary disease across the spectrum from mild to severe disease. Unfortunately,
atients undergoing LVRS do not span this spectrum; all operative candidates have
xtremely advanced emphysema and fall toward the severe end. The article of
ederer and colleagues1 exemplifies this finding in that more than 90% of their
atients were at the extreme in all four dimensions of the index (percentage of
redicted forced expiratory volume in 1 second, 6-minute walk, modified Medical
esearch Council dyspnea score, and body mass index). With all patients clustered
ogether at one end of the spectrum, the BODE is inherently limited in its ability to
iscriminate between patients likely to respond and those likely to have extreme
orbidity and mortality.
The study also illustrates both the good and the bad effects that have emanated
rom the National Emphysema Treatment Trial (NETT). The good is exemplified in
he remarkably low morbidity evidenced in the patient population reported in the
rticle. The NETT clearly and definitively identified the optimal candidate profile
nd thus allowed the selection of patients with the lowest risk-benefit ratio. The
uperb results of the patients who were chosen according to the final NETT
ecommendations are a testament to the value of this multi-institutional randomized
rial.
The trial, however, has also had a chilling and detrimental effect on the referral
f patients with end-stage emphysema for consideration of LVRS. The first article
utlining results from the NETT trial documented poor results in a subset at very
igh risk, and thereafter referrals to the trial markedly declined.2 Many NETT
nvestigators believe that this occurred because the public and the medical commu-
ity misinterpreted the conclusions as suggesting that LVRS was too risky to
ndertake for any patient. Others believe that the relative inaccessibility of LVRS
only 17 NETT sites throughout the country throughout the 7-year duration of the
rial) served to dampen the interest of internists and pulmonologists who would have
therwise referred patients for this potentially lifesaving intervention. In effect, both
atients with end-stage emphysema and their caregivers either forgot about or lost
nterest in LVRS during this prolonged period. Whatever the reasons, it is note-
orthy that in 2004 (the most recent year for which figures are available) only 254
atients in the entire country underwent LVRS (Current Procedural Terminology
ode 32491) paid for under Medicare (data obtained from Centers for Medicare &
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Ledicaid Services 2004 database). This occurred even
hough 42 centers have been approved to perform LVRS
ince 2002. The number of patients with end-stage emphy-
ema likely exceeds 100,000, so this remarkably small
umber of surgical interventions suggests severe underuse
f what is for many a potentially lifesaving procedure that
lso significantly improves both exercise capacity and qual-
ty of life.
Although I do not believe that the BODE index is likely
o provide the surrogate data points necessary to reliably
redict long-term survival, I congratulate the authors on
heir excellent results and their continued work in the field
f LVRS. It is important for all participants in LVRS
rograms to continue investigating and promoting LVRS in
The Journal of Thoraciche hope of reminding both patients and their physicians of
he remarkable improvement that can be achieved. Until
eferrals for LVRS vastly increase, this remains an unreal-
zed improvement.
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